3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
84
Lymphoma, Non-Hodgkin
71
Lymphoma
62
Lymphoma, Follicular
58
Lymphoma, Mantle-Cell
57
Lymphoma, Large B-Cell, Diffuse
40
Multiple Myeloma
36
Hodgkin Disease
30
Lymphoma, B-Cell, Marginal Zone
28
Recurrence
27
Lymphoma, B-Cell
19
Leukemia
18
Waldenstrom Macroglobulinemia
14
Neoplasms
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Neoplasms, Plasma Cell
8
Lymphoma, T-Cell
7
Leukemia, Myeloid, Acute
7
Burkitt Lymphoma
7
Lymphoma, T-Cell, Peripheral
6
Leukemia, B-Cell
6
Hematologic Neoplasms
6
Sezary Syndrome
5
Myelodysplastic Syndromes
5
Mycosis Fungoides
5
Immune System Diseases
5
Small Cell Lung Carcinoma
4
Lymphoma, T-Cell, Cutaneous
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Large-Cell, Anaplastic
4
Interventions
pembrolizumab
188
Cisplatin
47
Paclitaxel
45
Carboplatin
44
lenvatinib
31
Docetaxel
23
Pemetrexed
21
Fluorouracil
20
Capecitabine
17
Gemcitabine
15
Oxaliplatin
14
Saline Solution
13
Albumin-Bound Paclitaxel
11
130-nm albumin-bound paclitaxel
10
epacadostat
9
Leucovorin
9
Cetuximab
9
olaparib
7
Irinotecan
7
Bevacizumab
7
Etoposide
6
enzalutamide
5
belzutifan
5
Dexamethasone
5
durvalumab
4
Surgical Procedures, Operative
4
Radiotherapy
4
Nivolumab
4
trifluridine tipiracil drug combination
3
spartalizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Bendamustine Hydrochloride
×
Clear all
NCT05508867
2026-01-20
MK-4280A-008
Merck Sharp & Dohme LLC
Phase 2
Completed
203 enrolled